XU Fei, LI Pei-yong. Randomized Phase Ⅱ RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 92-95. DOI: 10.12019/j.issn.1671-5144.2023.02.006
|
Citation:
|
XU Fei, LI Pei-yong. Randomized Phase Ⅱ RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 92-95. DOI: 10.12019/j.issn.1671-5144.2023.02.006
|
XU Fei, LI Pei-yong. Randomized Phase Ⅱ RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 92-95. DOI: 10.12019/j.issn.1671-5144.2023.02.006
|
Citation:
|
XU Fei, LI Pei-yong. Randomized Phase Ⅱ RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 92-95. DOI: 10.12019/j.issn.1671-5144.2023.02.006
|
DownLoad: